Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patidegib topical gel extension study in adults with Gorlin syndrome
NL-OMON49176Phase 3Active, not recruiting
- Sponsor
- PellePharm
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of patidegib in Basal cell nevus syndrome (BCNS) and basal cell carcinoma (BCC), sponsored by PellePharm. Primary endpoints: Number of facial lesions suspicious for basal cell carcinoma, Number of suspicious facial lesions surgically removed and 2 more. Started Jul 2020; status: active, not recruiting.
02
Drugs
patidegib
03
Conditions
Basal cell nevus syndrome (BCNS)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NL-OMON49176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49176.